D. Lynn Kirkpatrick
D. Lynn Kirkpatrick founded Phusis Therapeutics, Inc. and ProlX Pharmaceuticals Corp. Presently, Dr. Kirkpatrick occupies the position of President, Chief Executive Officer & Director at Ensysce Biosciences, Inc.
In her past career she occupied the position of President & Chief Executive Officer for ProlX Pharmaceuticals Corp., President, Chief Executive Officer & Director at Ensysce Biosciences, Inc., Chief Scientific Officer for Biomira, Inc., Chief Scientific Officer of Cascadian Therapeutics LLC and Professor at the University of Regina.
Dr. Kirkpatrick received an undergraduate degree and a doctorate from the University of Saskatchewan.
Transactions
Date
Transaction
Value
| 05/26/2022 | 27,000 | Acquisition at $0.53 per share. | 14,310 |
| 05/25/2022 | 70,000 | Acquisition at $0.49 per share. | 34,300 |
| 06/30/2021 | 284,851 | Award at $0 per share. | 0 |
